Boston Scientific Corporation $BSX Shares Sold by K.J. Harrison & Partners Inc

Posted by Geri Gentry on Jul 6th, 2026

Boston Scientific logo K.J. Harrison & Partners Inc trimmed its stake in Boston Scientific Corporation (NYSE:BSX – Free Report) by 91.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,066 shares of the medical equipment provider’s stock after selling 42,717 shares during the period. K.J. Harrison & Partners Inc’s holdings in Boston Scientific were worth $255,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BSX. Brighton Jones LLC increased its position in shares of Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after purchasing an additional 226 shares in the last quarter. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific in the 2nd quarter valued at about $26,000. Main Street Financial Solutions LLC grew its stake in Boston Scientific by 35.3% during the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock worth $812,000 after buying an additional 1,971 shares during the last quarter. Ieq Capital LLC grew its stake in Boston Scientific by 97.0% during the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock worth $13,275,000 after buying an additional 60,860 shares during the last quarter. Finally, HUB Investment Partners LLC increased its position in Boston Scientific by 56.2% during the second quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock worth $763,000 after buying an additional 2,556 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Down 0.1%

Boston Scientific stock opened at $45.09 on Monday. The stock has a 50 day moving average of $50.99 and a two-hundred day moving average of $69.27. Boston Scientific Corporation has a twelve month low of $42.25 and a twelve month high of $109.50. The stock has a market capitalization of $67.01 billion, a price-to-earnings ratio of 18.86, a PEG ratio of 0.86 and a beta of 0.58. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX – Get Free Report) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same quarter in the previous year, the company posted $0.75 earnings per share. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, research analysts expect that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific announced that its Board of Directors has authorized a share buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s management believes its shares are undervalued.

Insider Buying and Selling at Boston Scientific

In other news, Director Cheryl Pegus bought 1,770 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was bought at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the purchase, the director owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director David C. Habiger bought 2,250 shares of the stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the acquisition, the director owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This represents a 19.35% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders have bought 9,800 shares of company stock valued at $554,012. 0.34% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

BSX has been the subject of several research analyst reports. The Goldman Sachs Group set a $71.00 price objective on Boston Scientific in a report on Thursday, May 28th. Robert W. Baird set a $70.00 target price on shares of Boston Scientific in a report on Thursday, May 28th. Zacks Research downgraded shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a research report on Friday, June 5th. Stifel Nicolaus decreased their price target on shares of Boston Scientific from $75.00 to $65.00 and set a “buy” rating for the company in a research note on Thursday, June 25th. Finally, Wolfe Research downgraded shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a research report on Friday, May 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $83.36.

Read Our Latest Stock Analysis on Boston Scientific

About Boston Scientific

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.